GnRH antagonist
Degarelix
Answer
Degarelix is authorised or registered in the US, the EU, the UK, Canada, Australia, Switzerland, Brazil and Singapore: 8 of the 10 registers read. Highest trial phase: Phase 3 (7 phase 3 trials, 0 with posted results). It has 187 registered trials, 51 of them running. Brand names on the FDA label register: Firmagon.
RegulatorTrial register10 regulators' registers, read 2026-09-03 to 2026-10-03 · ClinicalTrials.gov and EU CTIS, read 2026-10-03
Not medical, legal or regulatory advice.
187 trials by status
Trial registerClinicalTrials.gov and EU CTIS · read 2026-10-03 · 51 trials have posted results
Trials first submitted per year
Trial registerClinicalTrials.gov first-submitted date, last 10 years · read 2026-10-03. 2026 is not complete. 108 trials carry no first-submitted date (EU CTIS publishes none, or the year is outside this range).
Status by jurisdiction
World map| Where | Status | Register | Read |
|---|---|---|---|
| United States | FDA-approved | FDA, openfda | 2026-10-03 |
| European Union | Authorised | EMA, ema | 2026-10-03 |
| United Kingdom | Authorised | MHRA, uk-mhra | 2026-10-03 |
| Canada | Authorised | Health Canada, ca-dpd | 2026-10-03 |
| Australia | Registered | TGA, au-artg | 2026-10-03 |
| Switzerland | Authorised | Swissmedic, ch-swissmedic | 2026-10-03 |
| Brazil | Registado | ANVISA, br-anvisa | 2026-10-03 |
| Serbia | Not on the register | ALIMS, rs-alims | 2026-09-03 |
| Singapore | Registered | HSA, sg-hsa | 2026-09-03 |
| Turkey | Not on the register | TITCK, tr-titck | 2026-09-03 |
An EU decision applies in the 30 territories the EU register covers: its member states, and Iceland, Liechtenstein and Norway. A dashed tile has no register read for this peptide.
Side effects
Trial registerCHANGE ALERTS
Get an email when this changes
One email when the status of Degarelix changes on the register. You confirm your address first.
REGISTERED TRIALS
Newest 10 of 187 trials
| NCT01630967 | Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive C withdrawn before enrolling anyone · register updated 2026-10-01 |
|---|---|
| NCT04989946 | Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, H running, but no longer enrolling · register updated 2026-09-30 |
| NCT03070886 | Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Remov running, but no longer enrolling · register updated 2026-09-14 |
| NCT07335796 | A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer running, but no longer enrolling · register updated 2026-09-11 |
| 2023-509494-23-00 | DARIUS : A RANDOMIZED NON-COMPARATIVE PHASE II MULTICENTRIC TRIAL ON SHORT TERM DAROLUTAMIDE (ODM-201) CONCOMITANT TO RADIATION TH no status recorded · register updated 2026-09-07 |
| 2025-521859-23-00 | A phase Ib/II open-label, multi-center study of the DNA protein kinase inhibitor AMO959 with lutetium (177Lu) vipivotide tetraxeta no status recorded · register updated 2026-09-03 |
| NCT02005887 | TRial on the Endocrine Activity of Neoadjuvant Degarelix completed · register updated 2026-09-02 |
| NCT04633252 | A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Doc currently recruiting participants · register updated 2026-08-28 |
| 2022-503040-41-00 | An international prospective open-label, multi-center, randomized, non-comparative phase II study of lutetium [177Lu] vipivotide t no status recorded · register updated 2026-08-26 |
| NCT05501704 | ETHAN - ET for Male BC currently recruiting participants · register updated 2026-08-24 |
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.